Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Open-label, Single-arm Study to Investigate the Efficacy and Safety of Triptorelin Pamoate 22.5 mg 6-month Formulation in Chinese Patients With Locally Advanced or Metastatic Prostate Cancer

NCT05590793 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT05590793
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05590793 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Open-label, Single-arm Study to Investigate the Efficacy and Safety of Triptorelin Pamoate 22.5 mg 6-month Formulation in Chinese Patients With Locally Advanced or Metastatic Prostate Cancer
Lead sponsor
Ipsen
Phase
Phase 3
Overall status
Completed
Start date
November 17, 2022
Completion date
August 20, 2024
Enrollment
195 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

advanced prostate cancer, locally advanced prostate cancer, metastatic prostate cancer